Fam Med - SUTM Ambu/CF(1-3) Flashcards

1
Q

HTN - classification (adult >18)

A

Normal—SBP<120 and DBP<80

Elevated—SBP 120-139 or DBP 80-89 (pre-HTN => require lifestyle modification)

Stage I—SBP 140-159 or DBP 90-99 (HTN definition BP > 130/80)

StageII—SBP≥ 160 or DBP≥100

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

HTN - HTN urgency and emergency

A

Urgency (severe) SBP >180 and/or DBP >120 - in an asymptomatic patient

Emergency = severe HTN with end-organ damage (neurologic, MI, aortic dissection)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

HTN - antihypertensive meds for pregnant women

A

Contraindicated - ACEi, ARB, thiazide, Ca++ channel blockers

Safe: ß-blockers, hydralazine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

HTN- what to do when patient presents with moderate-to-severe HTN?

A

Initiating therapy right away - DON’T wait 1-2 months to confirm diagnosis and start treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

HTN - Thiazide side-effects

A

HYPOKALEMIA

hyperuricemia, hyperglycemia, elevation of cholesterol and triglyceride levels, metabolic alkalosis, hyperuricemia, hypomagnesemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

HTN - ß-blockers side-effects

A

Bradycardia, bronchospasm, sleep disturbances (insomnia), fatigue, may increase TGs and decrease HDL, depression, sedation, may mask hypoglycemic symptoms in diabetic patients on insulin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

HTN - ACEi side-effects

A

Acute renal failure, hyperkalemia, dry cough, angioedema, skin rash, altered sense of taste

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

HTN - Ca++ channel blockers side effects

A

Dihydropyridines (e.g., amlodipine): peripheral edema

Nondihydropyridines (e.g., verapamil, diltiazem): heart block

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

HTN - initial mono-therapy option? Is there any difference?

A

Thiazide, ACEi, ARBs, and Ca++ channel blockers (dihydropyridine)

There is little difference.

Most patients eventually need more than 1 drug to attain goal BP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

HTN - what to do if “white coat HTN” is suspected?

A

Twenty-four–hour ambulatory blood pressure monitoring is the most effective.

Home blood pressure monitoring is an alternative.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

HTN - Principles of treatment - target BP

A

≤60 => BP ≤ 140/90

>60 => BP ≤ 150/90

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

HTN - Principles of treatment - What to do when mono-therapy is ineffective?

A
  1. Increase dose to maximum
  2. Add 2nd meds (ACCOMPLISH trial show ACEi and CCB combination is effective) and increase dose of each to max
  3. Consider 3rd agent and referral to HTN specialist
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

HTN - Lipid screening for pt with and without CAD risk

A

With CAD risk (family history, obesity) => screen with fasting lipid profile every 5 years starting age 20

Without CAD risk => screen women ≥45y/o and men ≥35y/o

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Hyperlipidemia - Risk factors for CAD in patient with hyperlipidemia - Clinical pearl

A

Current cigarette smoking (dose-dependent risk)
HTN
Diabetes mellitus
Low HDL cholesterol (<35 mg/dL); high HDL (>60 mg/dL) is a NEGATIVE risk factor (subtract 1 from total)

Male: >45 years of age Female: >55 years of age
Male gender—if you count as a risk factor, do not count age Family history of premature CAD
MI/sudden death in male first-degree relative <55 years of age MI/sudden death in female first-degree relative <65 years of age

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Hyperlipidemia - Risk factors - Diet

A

Saturated fatty acid and cholesterol => Elevated LDL and total cholesterol

High-calorie diets => increase triglyceride (TG) levels

Alcohol => increase TG levels and HDL levels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Hyperlipidemia - Risk factors - Medications

A

Thiazides—increase LDL, total cholesterol, TG (VLDL)

β-Blockers (propranolol)—increase TGs (VLDL) and lower HDL

Estrogens—TG further increased in patients with hypertriglyceridemia

Corticosteroids and HIV protease inhibitors => elevate serum lipids

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Hyperlipidemia - Potency of statins

A

High intensity: atorvastatin 40 to 80 mg, rosuvastatin 20 to 40 mg

Moderate intensity: atorvastatin 10 to 20 mg, rosuvastatin 5 to 10 mg, simvastatin 20 to 40 mg, lovastatin 40 mg, pravastatin 40 to 80 mg, fluvastatin XL 80 mg (or 40 mg twice daily), pitavastatin 2 to 4 mg

Low intensity: simvastatin 10 mg, pravastatin 10 to 20 mg, lovastatin 20 mg, fluvastatin 20 to 40 mg, pitavastatin 1 mg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Hyperlipidemia - Four Categories of Patients Aged >21 yrs Who Benefit From Statin Therapy

A

Clinical ASCVD => High-intensity statin

LDL cholesterol ≥190 mg/dL => High-intensity statin

Diabetic patients aged 40–75 yrs with LDL cholesterol 70–
189 mg/dL
ASCVD risk score <7.5% => moderate-intensity
ASCVD risk score ≥7.5% => high-intensity statin

Nondiabetic patients aged 40–75 yrs with LDL cholesterol 70–189 mg/dL
ASCVD risk score ≥7.5% => moderate- to high- intensity statin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Hyperlipidemia - Dyslipidemia Syndrome

A

Type I: exogenous hyperlipidemia => chylomicron => Diet

Type IIa: familial hypercholesterolemia => LDL => Statins/Niacin/Cholestyramine

Type IIb: combined hyperlipoproteinemia => LDL+VLDL => Statins/Niacin/Gemfibrozil

Type III: Familial dysbetalipoproteinemia => IDL => Gemfibrozil/Niacin

Type IV: Endogenous hyperlipidemia => VLDL => Niacin/Gemfibrozil/Statins

Type V: Familial hypertriglyceridemia => VLDL+chylomicron => Niacin/Gemfibrozil

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Case File - Health maintenance - Level of prevention

A

Primary: prevent disease before it occurs (vaccines, education/exercise. removal of colon polyps…)

Secondary: promote early detection of disease (mammogram, eye exam for glaucoma…)

Tertiary: therapeutic and rehabilitative once disease is diagnosed (meds, stroke rehab, chronic pain management…)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Case File - Health maintenance - Cardiovascular screening tests recommendation

A

≥ 18yo => HTN (by BP measurement) => level A

≥ 35, M and ≥ 45, F => lipid disorders => level A
≥ 20, with increased risk => lipid disorders => level B

45 ≤ M ≤ 79 => take aspirin daily (reduce MI) => level A

US Abdominal aortic aneurysm (AAA) => 65 ≤ M, smoked ≤ 75 => level B
=> same age, never smoked => C
=> F, never smoked => D
=> F, smoked => I

Routine ECG, stress test, CT => low risk => D
=> moderate risk => I

22
Q

Case File - Health maintenance - Cancer screening

A

≥ 50 => colorectal cancer (FOBT, sigmoidoscopy, colonoscopy) => A

Prostate cancer (PSA, digital examination) => D

50 ≤ F/M, 30 or more pack-year/quit less than 15y ≤ 80 => lung cancer (annual low-dose CT) => B

Asymptomatic => pancreatic testicular => D
Asymptomatic => bladder cancer => I

23
Q

Case File - Health maintenance - Other health conditions

A

Obesity (BMI) => all => B

Type 2 DM => asymptomatic => I
=> adult with HTN/hyperlipidemia => B

Depression => mechanism in place => B

Screen/promote cessation of tobacco use => A

Screen/prevent misuse alcohol => B

Routine Thyroid => asymptomatic => I

24
Q

Case File - Health maintenance - Immunization

A

Tdap booster => 19 ≤ all ≤ 65 (due to waning immunity to pertusis)

Influenza => ≥ 6months

Pneumococcal polysacde (PPSV-23) and pneumococcal conjugate (PCV-13) => ≥ 65
      => ≤ 65 (never vaccinated, immunocompromised)

Hep B => Healthcare workers, IV drug users, MSM, multiple sex partners, diabetes

Hep A => chronic liver disease, use clotting factors, IV drug users, MSM, travel to ongoing pandemic

Varicella => No known vaccination status, seronegative

Meningococcal => college dorm, military, complement def, asplenic

25
Q

Headache - emergency evaluation

A

Rule out intracranial bleed => non-contrast CT and lumbar puncture (for small bleed missed from CT)

26
Q

Headache - visual aura of migraine

A

bilateral homonymous scotoma => Bright, flashing, crescent-shaped images

27
Q

Case file - COPD exacerbation - management

A

ABC - airway, breathing, circulation

Rx: Oxygen, ß2 agonist (albuterol), corticosteroid (act slowly, need to administer with ß2 agonist [bronchodilators] to improve short term outcomes

Inhaled anti-cholinergic (ipratropium) may work synergistically with ß2 agonist

28
Q

Case File - COPD - most common etiology of COPD? 2 common types of COPD?

A

Cigarettes

Chronic bronchitis (cough + sputum for 3 months in 2 consecutive years)
Emphysema (lung tissues destruction => enlargement of respiratory bronchioles)
29
Q

Case file - COPD - what does dyspnea indicate?

A

Lung function (measured by FEV1) is reduced about half and COPD has presented for years

30
Q

Case File - COPD - which value of spirometry indicates reversibility in COPD?

A

[FEV1]/[FVC] when FEV1 is increased ≥ 12% or 200ml

31
Q

Case File - COPD management (in general)

A

Goal:
- relieve symptoms, slow disease progression, prevent exacerbations/complications

  • Encourage pt to quit smoking
  • Vaccination: pneumococcal and influenza
32
Q

Case File - COPD - relationship between smoking cessation and COPD progression

A

smoking cessation DOES NOT result in significant improvement in pulmonary function

smoking cessation DOES reduce the rate of further deterioration to that of a nonsmoker.

33
Q

Case File - COPD - Treatment recommendation for stage I

A

Short acting bronchodilators (PRN) => ß2-agonist (albuterol), anti-cholinergic (ipratropium)

Inhaler&raquo_space;> oral = less side-effects

34
Q

Case File - COPD - Treatment Recommendation for COPD stage II

A

long-acting bronchodilators are added

- ß2-agonist (salmeterol)
- anticholinergic (tiotropium)
35
Q

Case File - COPD - Treatment Recommendation for COPD stage III and IV

A

Inhaled steroids (fluticasone, triamcinolone, mometasone, etc) = for stage III and IV with frequent exacerbation

** long term use of steroid is not recommended - myopathy, glucose intolerance, osteoporosis **

O2 therapy = for stage IV with evidence of hypoxemia (Pa02 ≤ 55 mm Hg or Sa02 ≤ 88% at rest)

36
Q

Case file - COPD - which therapy is the only intervention that has been shown to decrease mortality?

A

O2 therapy

must be worn for at least 15 h/d.

37
Q

Case file - COPD - when to treat exacerbation with antibiotics? which bacteria is the most common cause?

A

Exacerbations associated with increased amounts of sputum or with purulent sputum

A sputum culture should be performed.

 - Pneumococcus
 - Haemophilus injluenzae
 - Moraxella catarrhalis
    • Mild - can be directed towards these organisms
    • Severe - may have gram (-) like Klebsiella or Pseudo => broader antibiotics
38
Q

Case file - COPD - Classification of COPD severity

A

Stage 0 - At risk
Cough, sputum production. Normal spirometry
Vaccines and address risk factors (exposure to tobacco smoke, occupational dust/chemicals, or smoke from home cooking/ heating fuel)

Stage I - Mild COPD - FEV, fFVC <0.7
FEV => 80% predicted
=> Short-acting bronchodilators

Stage II - Moderate COPD - FEV, fFVC <0.7
FEV => 50%-80% predicted
=> Long-acting bronchodilators

Stage Ill - Severe COPD - FEV, fFVC <0.7
FEV, 30%-50% predicted
=> Inhaled steroids

Stage IV - Very severe COPD - FEV, fFVC <0.7
FEV, <30% predicted
FEV, <50% predicted with chronic hypoxemia
=> Long-term oxygen therapy and consider surgical interventions

39
Q

Upper Respiratory Disease - Cough - Postnasal drip mechanism

A

The mucosal receptors in the pharynx and larynx are stimulated by secretions of the nose and sinuses that drain into the hypopharynx

40
Q

Upper Respiratory Disease - Cough - Viral vs. Bacterial URI features

A

Viral: Myalgia, rhinorrhea, headache, fever, cough

Bacterial: yellow sputum, fever, cough

41
Q

Upper Respiratory disease - Sinusitis - signs to consider acute bacterial sinusitis

A

If a patient has a cold beyond 8 to 10 days, or if the cold symptoms improve and then worsen after a few days (“double-sickening”)

Can be secondary to an initial viral infection

42
Q

Upper Respiratory disease - Sinusitis - antibiotic treatment course

A

Treat with antibiotics and decongestants for 1 to 2 weeks, depending on severity.

=> If there is no improvement after 2 weeks of therapy, then sinus films and a penicillinase-resistant antibiotic are appropriate.

Consider ENT consultation.

Antibiotics use: Amoxicillin, amoxicillin-clavulanate, TMP/SMX, levofloxacin, moxifloxacin, and cefuroxime are good choices.

43
Q

Upper Respiratory disease - Sinusitis - treatment: antihistamine

A

Reserve for patients with allergies; use discriminately because of the “drying effect” => can worsen congestion

Loratadine (Claritin), fexofenadine (Allegra), chlorpheniramine (Chlor- Trimeton)

44
Q

Case File - Joint pain - what to rule out when patient presents with monoarticular joint pain? How to do so?

A

Need to exclude infectious arthritis, as cartilage can be damaged within the first 24h

Joint aspiration

45
Q

Case File - Joint pain - which meds can induce hyperurecemia?

A

Thiazide => increase urinary urate reabsorption

Loops diuretics, chemotherapeutics

46
Q

Case File - Joint pain - stages of Gout

A

(1) asymptotic tissue deposition of crystals
(2) acute gout flares
(3) inter-critical segments (occurring after an acute flare, but before the next flare)
(4) chronic gout (symptoms of chronic arthritis and/or tophi)

47
Q

Case File - Joint pain - How is the serum uric acid level during gout attack?

A

Can be normal or even low

48
Q

Case File - Joint pain - infectious arthritis

A

Bacterial => 90% mono, large joint (hip, knee, shoulder)

Fungi/mycobacteria => chronic mono or 2-3 joints

Acute poly (≥ 3 joints) => endocarditis or disseminated gonococcal infection

Labs: arthrocentesis, blood culture, Gram stain and culture, CBC and erythrocyte sedimentation rate (ESR)

49
Q

Case File - Joint pain - RA diagnosis criteria

A

Synovitis (swelling) in at least 1 joint

≥ 6 points total for: number of joints, serologic (RF, anti-CCP), elevated acute phase protein (CRP, ESR), symptom duration (≥ 6 weeks)

50
Q

Case File - Joint pain - Treatment for septic arthritis, OA, RA

A

Septic arthritis = IV antimicrobials and surgery for drainage of the infected joint.

Degenerative joint (OA) = mobility exercise, weight loss, surgery, corticosteroid (one per 4-6 months to avoid cartilage destruction)

RA = education, exercise, PT, OT = DMARDs (sulfasalazine, methotrexate), TNFå inhibitors (infliximab, etanercept)